Capsugel, a division of Pfizer, is offering its Vcaps hydroxypropyl methyl cellulose (HPMC) capsules for use in dry powder inhalation products.

A division of Pfizer, Capsugel is the world-leading supplier of two-piece gelatin capsules. Capsugel serves the global pharmaceutical and dietary supplement markets from ten production centers, located in the USA , Europe, Japan, India and the Far East.

Capsugel provides the widest capsule product range, including Coni-Snap® pure certified gelatin capsules, Vcaps® and NPcaps™ vegetarian capsules and innovative Licaps® liquid-filled capsules. The company is offering its Vcaps for use in dry powder inhalation products. The announcement follows a licensing agreement between Capsugel and Teijin Pharma which allows Capsugel to license Teijin's entire patent portfolio related to the use of HPMC capsules for inhalation products.

The capsules are two-piece capsules made from HPMC as the primary film-forming material, instead of gelatine – which is currently the most common component of capsules. The advantage in dry powder inhalers is the capsules do not fracture into small pieces making the products safer. As an alternative to gelatine capsules, the company said HPMC capsules could be used for inhalation treatments beyond the traditional ones for asthma and chronic obstructive pulmonary disorder.

Capsugel offers a comprehensive array of product and support services to the dietary supplement market. Companion products include a full line of capsule filling machines and replacement parts. Softgels are offerred to our European markets. Capsugel also provides industry-leading services, including custom color and print development, technical services, regulatory support and liquid-formulation development